Glaucoma Clinical Trials
To learn more about clinical trials on treatments for eye disease please call or email the contact for the specific study below.
For a longer list of studies needing volunteers throughout the U-M Health System, please go to UMClinicalStudies.
On this page:
Title: The eyeGuide: Piloting a personalized behavior change program for non-adherent glaucoma patients
IRB Number: HUM00112614
Despite evidence that medication reduces vision loss from glaucoma, it remains the second leading cause of blindness in the United States. A critical barrier to preventing vision loss is that about one-half of glaucoma patients are essentially “untreated” because they do not follow the schedule to take their glaucoma medications.
The purpose of this research study is test the impact of two personalized technology-based programs that may help patients remember to take their glaucoma medication.
•Be at least 40 years of age or older
•Have a diagnosis of glaucoma
•Currently be prescribed to take 1 or more glaucoma medications
•Have difficulty remembering to take your glaucoma medication(s)
•Laurie Taylor, COT (734) 232-8057, firstname.lastname@example.org
•Principal Investigator: Paula Anne Newman-Casey, MD
Title: The efficacy and safety of Bimatoprost sustained release (SR) in patients with open angle glaucoma or ocular hypertension (ARTEMIS)
Glaucoma is a group of eye conditions resulting in optic nerve damage, which may cause vision loss. Ocular hypertension is when the pressure inside the eye (intraocular pressure or IOP) is higher than normal. Ocular hypertension can develop into glaucoma. The purpose of the study is to investigate the safety and effectiveness of two different dose strengths (10 µg or 15 µg) of Bimatoprost sustained release (SR) compared to treatment with Timolol 0.5% eye drops in lowering eye pressure in patients with open-angle glaucoma or high eye pressure.
Study participation is 20 months (23 visits to the research clinic and 6 phone calls) if and after you qualify. You will receive study-related care and investigational medication at no cost.
- ≥ 18 yrs old
- Men and Women
- Any ethnicity, race, smoking status
- Open-Angle Glaucoma and/or Ocular Hypertension (both eyes, requiring eye pressure lowering medication)
- Willing to stop your eye pressure lowering drugs as instructed by the study doctor
Title: Comprehensive ocular telemedicine assessment
IRB Number: HUM00072885
The purpose of this research is to identify methods that improve the usefulness, reliability, and validity of ophthalmic photographs that test for eye disease, vision, eye care questionnaire to help identify visual problems, increase eye care access in underserved communities, and provide a way to set up programs for eye disease screening.
Title: Comparison of ophthalmic testing instruments
IRB Number: HUM#00071125
Ophthalmologists measure eye structures and functions using many techniques. We were interested in directly comparing the results of two tools, Snellen visual acuity (VA) and the Titmus vision screening VA instrument, to determine whether different ophthalmic assessments provide similar results in the same patients.
Title: Smartphone screening for eye diseases
IRB Number: HUM#00097907
Ocular cellscope is a smart phone-based camera capable of capturing high-quality, wide field images of the retina. Increasing the accessibility and portability of the retinal exam holds great promise in improving the reach of ophthalmic care, in both the remote community and inpatient settings.
This is a multi-site cross-sectional diagnostic study is also being conducted at San Francisco General Hospital. At each site, we will approach patients in the ophthalmology clinic. Study will test the feasibility and accuracy of a smartphone based camera for diagnosing eye diseases.
Title: OHTS 20-Year Follow-up
IRB Number: HUM#00106865
The Ocular Hypertension Treatment Study (OHTS) 20-year follow-up is an observational study of 1,636 participants who were originally enrolled in 1994-1996 in a randomized clinical trial conducted to determine whether ocular hypotensive medication to lower intraocular pressure in ocular hypertensive individuals prevented/delayed the onset of primary open angle glaucoma.
OHTS Phase 3 will re-examine study participants 20 plus years after enrollment to document clinical status and the incidence and severity of self-reported functional limitations.
All subjects previously participated in the OHTS study will be contacted for the OHTS phase 3 study.
Title: Glaucoma and Biomarkers
IRB Number: HUM00052276
Glaucoma is a major cause of blindness. The inability to predict a patient’s eye pressure response to medications is a critical barrier for the clinician to consistently provide highly effective eye pressure-based treatments. Current trial-and error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive factors for drug response. Our research project will address this critical barrier by focusing on physiological factors that predict eye pressure response to drugs. The purpose of our study is to improve glaucoma outcomes by identifying biomarkers and environmental factors that profile a patient at risk for glaucoma by age-of-onset, rate of disease progression, “poor response” to treatment, and large eye pressure fluctuation.